Michael Burkes Brophy Sells 705 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 705 shares of the company’s stock in a transaction on Thursday, April 25th. The stock was sold at an average price of $89.55, for a total transaction of $63,132.75. Following the transaction, the chief financial officer now owns 71,397 shares of the company’s stock, valued at approximately $6,393,601.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The shares were sold at an average price of $91.38, for a total transaction of $139,171.74.
• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total transaction of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total transaction of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The shares were sold at an average price of $88.36, for a total transaction of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total transaction of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The shares were sold at an average price of $67.73, for a total transaction of $1,509,092.13.
• On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The shares were sold at an average price of $65.09, for a total transaction of $210,566.15.

Natera Stock Up 0.4 %

Shares of NASDAQ:NTRA traded up $0.38 during trading on Friday, reaching $91.66. The stock had a trading volume of 568,943 shares, compared to its average volume of 1,445,065. Natera, Inc. has a one year low of $36.90 and a one year high of $98.82. The company has a market capitalization of $11.07 billion, a P/E ratio of -24.18 and a beta of 1.37. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. The firm’s 50-day simple moving average is $87.72 and its 200 day simple moving average is $67.16.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The business had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. As a group, research analysts expect that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NTRA. Craig Hallum began coverage on shares of Natera in a research note on Monday, April 8th. They issued a “buy” rating and a $117.00 price target on the stock. Piper Sandler raised their price target on shares of Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. BTIG Research raised their price target on shares of Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, December 29th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target on the stock in a research note on Friday, April 5th. Finally, Canaccord Genuity Group raised their price target on shares of Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. One analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $86.40.

Institutional Trading of Natera

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Natera by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock valued at $687,280,000 after buying an additional 588,147 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Natera by 0.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,556,792 shares of the medical research company’s stock worth $334,388,000 after purchasing an additional 67,102 shares in the last quarter. Kynam Capital Management LP boosted its stake in Natera by 3.6% in the 3rd quarter. Kynam Capital Management LP now owns 3,003,668 shares of the medical research company’s stock worth $132,912,000 after purchasing an additional 103,668 shares in the last quarter. RTW Investments LP boosted its stake in Natera by 1.5% in the 3rd quarter. RTW Investments LP now owns 2,651,783 shares of the medical research company’s stock worth $117,341,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Natera by 52.0% in the 3rd quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company’s stock worth $111,930,000 after purchasing an additional 865,404 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.